相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS)
Kumi Oshima et al.
ANNALS OF HEMATOLOGY (2012)
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study
Atsushi Wakita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Acute myeloid leukaemia in the elderly: a review
Daniel A. Pollyea et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Acute Myeloid Leukemia
Margaret R. O'Donnell et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome
A. K. Burnett et al.
LEUKEMIA (2011)
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations
Harshabad Singh et al.
LEUKEMIA RESEARCH (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Susan P. Whitman et al.
BLOOD (2010)
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Bob Lowenberg et al.
BLOOD (2010)
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
Larry D. Cripe et al.
BLOOD (2010)
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
Christoph Roellig et al.
BLOOD (2010)
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
Heiko Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
Brian L. McClune et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
Cecile Pautas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance
Hendrik J. M. de Jonge et al.
BLOOD (2009)
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005
Asa Rangert Derolf et al.
BLOOD (2009)
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Jean-Luc Harousseau et al.
BLOOD (2009)
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial
Alan K. Burnett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
Keith Wheatley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Age-Specific Differences in Oncogenic Pathway Dysregulation and Anthracycline Sensitivity in Patients With Acute Myeloid Leukemia
Arati V. Rao et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
Roberto Latagliata et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia
Sebastian Scholl et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century
Dianne Pulte et al.
HAEMATOLOGICA (2008)
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
Jean-Valere Malfuson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Acute myeloid leukemia in the elderly
Herve Dombret et al.
SEMINARS IN ONCOLOGY (2008)
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results
Arnaud Pigneux et al.
HAEMATOLOGICA (2007)
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
Claude Gardin et al.
BLOOD (2007)
Acute myeloid leukemia and myelodysplastic syndromes in older patients
Elihu Estey
JOURNAL OF CLINICAL ONCOLOGY (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
Francis J. Giles et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
Stefan Froehling et al.
BLOOD (2006)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia:: results from Cancer and Leukemia Group B 8461
Sherif S. Farag et al.
BLOOD (2006)
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission:: results of second randomization of the AML HD98-B treatment trial
RF Schlenk et al.
LEUKEMIA (2006)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
H Kantarjian et al.
CANCER (2006)
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
B van der Holt et al.
BLOOD (2005)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
RF Schlenk et al.
LEUKEMIA (2004)
6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group
T Büchner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
JE Anderson et al.
BLOOD (2002)
The outcomes and costs of acute myeloid leukemia among the elderly
J Menzin et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
D Grimwade et al.
BLOOD (2001)
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
AH Goldstone et al.
BLOOD (2001)
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
RM Stone et al.
BLOOD (2001)
分享论文
